Vertex Pharmaceuticals Inc VRTX
Stock research in plain language · As of Oct 04, 2026 · updated once a week, after the trading week closes
What the company does
Vertex Pharmaceuticals Inc is a large-cap company in the Healthcare sector (Biotechnology), with a market value of $127.9B, based in the USA.
It employs about 6,400 people and has been listed since Jul 24, 1991.
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor.
Cheap or expensive? priced in line with its group
Its price-to-earnings (P/E) is 29.5 versus 31.6 for the median of the Healthcare sector in our universe (22 companies) — priced in line with its group.
Revenue is growing 12% versus the same quarter last year.
On analysts' next-year forecasts the multiple drops to 24.1 — they expect higher earnings.
The average analyst price target is 571.39, 13% above the current price (their view, not ours).
The stock sits at 65% of its one-year range (0% = the low, 100% = the high).
The risks
- No risk flags were detected from the data we have.
Strengths
- ✅ Profitable — 33 of every 100 dollars of revenue stays as profit.
- ✅ Generates free cash flow — profit becomes cash in the bank.
- ✅ Buys back its shares (1% fewer shares in a year).
- ✅ More cash than debt.
- ✅ Most analysts rate it buy (26 vs 2).
What changed this week
Over the past week the stock fell 4.1% (for comparison: S&P 500 -0.2%, sector ETF XLV -2.6%).
This week's news
- Vertex (VRTX) or Regeneron (REGN)? Two Biotech Moats, Two Very Different Bets finance.yahoo.com · 2026-10-03
- Vertex Pharmaceuticals And 2 Other Top Gene Therapy Stocks finance.yahoo.com · 2026-10-01
- Vertex Pharmaceuticals (VRTX) Stock Falls Amid Market Uptick: What Investors Need to Know finance.yahoo.com · 2026-10-01
- Vortex Energy Completes Acquisition of the Meadows Project in Saskatchewan finance.yahoo.com · 2026-10-01
- Could Vertex Pharmaceuticals (VRTX)’s Kidney Breakthrough Unlock a New Opportunity for Maze Therapeutics (MAZE)? finance.yahoo.com · 2026-09-29
- 2 Healthcare Stocks to Target This Week and 1 We Avoid finance.yahoo.com · 2026-09-28
A description of facts from the filings and the market — not investment advice or a recommendation. "Cheap" and "expensive" are always relative to the comparison group.